Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
2025 August
  • Home
  • Archive for August, 2025
Global Trial Podcast
user

Host: Julio Martinez linkedin-img

user

Guest: Ross Youngs linkedin-img


×

Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere

  • August 29 2025
  • Video - Date: 08/28/2025
  • Length: 29.44 min

Summary –

Discussed in this Podcast

→ How microbiome mining could cure cancer, Alzheimer’s & more
→ Processing 2 MILLION liters of water daily to extract microbes
→ Accessing drug-like molecules that evolution perfected over 3.4 billion years
→ Why this could be worth TRILLIONS in the next 25 years
→ Transforming agriculture, cosmetics & environmental remediation

lightbulbKEY TAKEAWAY: “Microbes have always been chemical researchers and factories of life. Biosortia’s breakthrough technology now effectively opens the door to ALL microbes.” – Ross Youngs

This technology could literally transform how we discover new medicines and accelerate first-in human trials globally!

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI

  • August 15 2025

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI (August 15, 2025) by Mariam E Sunny. Summary Superluminal to receive payments, equity investment, royalties Lilly, Novo pursuing GPCR-targeting drugs for obesity Superluminal’s lead candidate not part of deal with Lilly. Aug 14 (Reuters) – Eli Lilly (LLY.N), has signed a deal worth $1.3 billion with privately

Continue Reading

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity

  • August 14 2025

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as well as additional development and commercial milestones, and tiered royalties (August 14, 2025) by Sarah Sutton. Boston, MA — August 14, 2025

Continue Reading

RSS Industry News

  • A non-invasive method for profiling the gut microbiome and virome of honey bee queens January 19 2026
  • Amplicon-based sequencing as a diagnostic tool for severe pneumonia in the ICU January 19 2026
  • Socioeconomic and nutritional determinants outweigh gut microbiota influence on neurodevelopment in young children from Antananarivo, Madagascar January 17 2026
  • Effects of exogenous selenium treatment on the composition of endophytic bacterial and fungal communities in Amorphophallus muelleri January 16 2026
  • Segmented filamentous bacteria in the gut protect against secondary bacterial infections in the lung January 16 2026
  • The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans January 15 2026
  • The microbiome at the centre of NAD+ supplementation January 15 2026
  • Chemical whispers hidden in the plant and microbiota kingdoms January 15 2026
  • Revealing and characterizing bacterial communities of in vitro Musa species through 16S rDNA metabarcoding and culture dependent approaches January 14 2026
  • Cholesterol-lowering effects of oats induced by microbially produced phenolic metabolites in metabolic syndrome: a randomized controlled trial January 14 2026
Quick Link
  • Products & Services
  • Blog
  • Contact
Recent Posts
  • The Billion Dollar Savings per Approved Drug
  • Evolution, Purpose, and the Leaders We Need Now, with Ross
  • Mining the Microbiome: Unlocking Hidden Chemistry at Scale-Driven Polypharmacology Drug Discovery by Monetizing Innovation
Sign up for our newsletter
Loading
Biosortia Microbiomics © 2026. All Rights Reserved.